cGMP-Aligned · FDA-Registered U.S. Facility · Third-Party COA on Every LotSupplied for Research Use Only
BioRegenEx · Research

MSC Exosomes for Multiple Sclerosis

← Back to Research Library

Mesenchymal stem cell (MSC)-derived exosomes are studied in regenerative research for multiple sclerosis and demyelinating disease. This overview is provided for research and educational purposes only.

What MSC exosomes are

MSC-derived exosomes are nanoscale, cell-free extracellular vesicles (roughly 30–150 nm) that carry signaling cargo such as proteins, lipids, and microRNA. They are not stem cells, and BioRegenEx supplies them as characterized, research-use-only material with per-lot documentation.

What the research explores

In preclinical models of multiple sclerosis and demyelination (such as EAE), MSC-derived exosomes have been studied for signaling related to remyelination, neuroinflammation, and immune modulation. These are research findings only. The studies are indexed in our Exosome Research Library under Neurological and Immunology.

Why sourcing and characterization matter

Because exosome composition depends on the source cells and manufacturing, research-grade material is defined by measurement — particle size and concentration, sterility and endotoxin screening, and a per-lot Certificate of Analysis.

Frequently Asked Questions

Are MSC exosomes an approved MS treatment?

No. They are not FDA-approved to treat multiple sclerosis or any condition and are supplied for research use only (RUO).

What does the MS research focus on?

Preclinical research focuses on remyelination and neuroinflammatory signaling.

For research and educational purposes; research-use-only.

These statements have not been evaluated by the FDA. BioRegenEx supplies MSC-derived exosomes for research use only (RUO); they are not intended to diagnose, treat, cure, or prevent any disease. This content is educational and is not medical advice.

Important Information

These statements have not been evaluated by the U.S. Food and Drug Administration. BioRegenEx products are not intended to diagnose, treat, cure, or prevent any disease.

Exosome therapy is an emerging regenerative approach. It is investigational, outcomes vary, and individual results cannot be guaranteed. Patient testimonials reflect individual experiences and are not representative of typical results.

References to regulatory standards — including Section 351(a) of the Public Health Service Act — describe the company’s stated quality and compliance approach and should not be interpreted as FDA approval or endorsement of any product.

This presentation is provided for educational and informational purposes only and does not constitute medical advice. Treatment decisions should always be made in consultation with a qualified, licensed healthcare provider.